Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma

Immune checkpoint blockade (ICB) therapy provides remarkable clinical gains, where melanoma is at the forefront of its success. However, only a subset of patients with advanced tumors currently benefit from these therapies, which at times incur considerable side-effects and costs. Constructing predi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Nat Med
Autores principales: Auslander, Noam, Zhang, Gao, Lee, Joo Sang, Frederick, Dennie T., Miao, Benchun, Moll, Tabea, Tian, Tian, Wei, Zhi, Madan, Sanna, Sullivan, Ryan J., Boland, Genevieve, Flaherty, Keith, Herlyn, Meenhard, Ruppin, Eytan
Formato: Artigo
Lenguaje:Inglês
Publicado: 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6693632/
https://ncbi.nlm.nih.gov/pubmed/30127394
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41591-018-0157-9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares